Synapse - Genitourinary Oncology Service

Results (53)

Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): An open-label, randomised, phase 3 trial

Journal Article

Fizazi, K.; Morris, M. J.; Shore, N.; Chi, K. N.; Crosby, M.; de Bono, J. S.; Herrmann, K.; Roubaud, G.; Nagarajah, J.; Fleming, M.; more...
Lancet Oncology (2025)

Fulltext@MSK | Save

Defining the role of pragmatic clinical trials in cancer clinical research: Outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer

Review

Cardoso Borges, F.; van der Graaf, W. T. A.; Saesen, R.; Aebi, S.; Amariutei, A. E.; Bekelman, J.; Gorlia, T.; Hulstaert, F.; Huys, I.; Kluetz, P.; more...
Lancet Oncology (2025)

Fulltext@MSK | Save

Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: A phase 1/2, first-in-human trial

Journal Article

Tendler, S.; Dunphy, M. P.; Agee, M.; O'Donoghue, J.; Aly, R. G.; Choudhury, N. J.; Kesner, A.; Kirov, A.; Mauguen, A.; Baine, M. K.; more...
Lancet Oncology (2024)

Fulltext@MSK | Save

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial

Journal Article

Necchi, A.; Roumiguié, M.; Kamat, A. M.; Shore, N. D.; Boormans, J. L.; Esen, A. A.; Lebret, T.; Kandori, S.; Bajorin, D. F.; Krieger, L. E. M.; more...
Lancet Oncology (2024)

Fulltext@MSK | Save

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial

Journal Article

Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): A single-arm, multicentre, phase 2 trial

Journal Article

Albiges, L.; Gurney, H.; Atduev, V.; Suarez, C.; Climent, M. A.; Pook, D.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Stus, V.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study

Journal Article

Pant, S.; Schuler, M.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Minchom, A.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): A multicentre, open-label, randomised, phase 3 trial

Journal Article

Fizazi, K.; Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): Extended follow-up from the phase 3, randomised, open-label study

Journal Article

Choueiri, T. K.; Eto, M.; Motzer, R.; De Giorgi, U.; Buchler, T.; Basappa, N. S.; Méndez-Vidal, M. J.; Tjulandin, S.; Park, S. H.; Melichar, B.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial

Journal Article

Smith, M. R.; Scher, H. I.; Sandhu, S.; Efstathiou, E.; Lara, P. N. Jr; Yu, E. Y.; George, D. J.; Chi, K. N.; Saad, F.; Ståhl, O.; more...
Lancet Oncology (2022)

Fulltext@MSK | Save